Wissenschaftliche Arbeiten

Prof. Dr. Bülent Karabulut

196 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Ege Üniversitesi Hastanesinde gastrointestinal sistem kanserlerinin epidemiyolojik ve sağ kalım özellikleri

    Ege Tıp Dergisi, 2019

    DOI 10.19161/etd.668440 Frei zugänglicher VolltextQuelle: ORCID

  2. Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy

    Turkish journal of medical sciences, 2019

    DOI 10.3906/sag-1808-114 PMID 30997793 17 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  3. The Evaluation of Effificacy and Tolerability of Regorafenib Treatment in Metastatic Colorectal Cancer: Single Center Experience

    Turkiye Klinikleri Journal of Medical Sciences, 2019

    DOI 10.5336/medsci.2018-64306 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  4. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with advanced breast cancer (ABC): Final results from EVEREXES

    Annals of Oncology, 2019

    DOI 10.1093/annonc/mdz418.003 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  5. Real-world assessment of clinical effectiveness and safety of pazopanib in patients with advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: A prospective, observational study (PARACHUTE)

    Annals of Oncology, 2019

    DOI 10.1093/annonc/mdz446.008 Frei zugänglicher VolltextQuelle: OpenAlex

  6. THE FREQUENCY AND CUNICAL OUTCOME OF CRESLENTIC GLOMERULONEPHRITIS AMONG 532 RENAL BIOPSIES

    DOAJ (DOAJ: Directory of Open Access Journals), 2019

    Frei zugänglicher VolltextQuelle: OpenAlex

  7. A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study)

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.4_suppl.26 5 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  8. The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome

    European journal of breast health, 2018

    DOI 10.5152/ejbh.2018.4170 PMID 30288495 17 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  9. The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients

    Nutrition, 2018

    DOI 10.1016/j.nut.2017.09.013 PMID 29429533 19 Zitationen (Europe PMC) Quelle: ORCID

  10. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

    Journal of Gastrointestinal Cancer, 2018

    DOI 10.1007/s12029-017-0047-2 PMID 29302856 19 Zitationen (OpenAlex) Quelle: OpenAlex

  11. Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study

    Surgical Oncology, 2018

    DOI 10.1016/j.suronc.2018.05.032 PMID 30217306 8 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  12. Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.4_suppl.346 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  13. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer

    British journal of surgery, 2018

    DOI 10.1002/bjs.10984 PMID 30155949 88 Zitationen (OpenAlex) Quelle: OpenAlex

  14. Angiogenesis inhibition on glioblastoma multiforme cell lines (U-87 MG and T98G) by AT-101

    Journal of Oncological Sciences, 2018

    DOI 10.1016/j.jons.2018.06.002 4 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  15. Nutrition-aware treatment approach has a prognostic impact in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

    Clinical Nutrition, 2018

    DOI 10.1016/j.clnu.2018.06.1311 Quelle: OpenAlex

  16. Metastatik Kolorektal Kanser Tedavisinde Hedefe Yönelik Ajanlar ve Kullanım Alanları

    Turkiye Klinikleri Medical Oncology - Special Topics, 2018

    Quelle: OpenAlex

  17. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study

    World Journal of Surgical Oncology, 2017

    DOI 10.1186/s12957-017-1275-4 PMID 29166925 24 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  18. Prognostic Factors for Isolated Locoregional Recurrences in Colon Cancer and Survival After Salvage Surgery: a Cohort Study

    Indian Journal of Surgery, 2017

    DOI 10.1007/s12262-017-1623-1 6 Zitationen (OpenAlex) Quelle: OpenAlex

  19. A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study)

    Journal of Clinical Oncology, 2016

    DOI 10.1200/jco.2016.34.4_suppl.tps182 21 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  20. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study

    Journal of Gastrointestinal Cancer, 2016

    DOI 10.1007/s12029-016-9823-7 PMID 27126591 2 Zitationen (OpenAlex) Quelle: OpenAlex

  21. Efficacy of obesity in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy combinations: A Turkish Oncology Group Study

    Annals of Oncology, 2016

    DOI 10.1093/annonc/mdw370.82 Frei zugänglicher VolltextQuelle: OpenAlex

  22. BİRİNCİ BASAMAK BEVASİZUMAB BAZLI TEDAVİLER KULLANAN METASTATİK KOLOREKTAL KANSERLİ HASTALARDA PRİMER TÜMÖRÜN REZEKSİYONUNUN PROGNOSTİK ÖNEMİ TÜRK ONKOLOJİ GRUBU ÇALIŞMASI

    Kocaeli Üniversitesi - AVESİS, 2016

    Quelle: OpenAlex

  23. Renal cell cancer: overview of the current therapeutic landscape

    Expert Review of Anticancer Therapy, 2016

    DOI 10.1080/14737140.2016.1222908 PMID 27548347 22 Zitationen (OpenAlex) Quelle: OpenAlex

  24. A Retrospective Comparative Study Of Intrinsic Moleculer Breast Cancer Subtypes Between Young And Elderly Women With Breast Cancer.

    Journal of Clinical Oncology, 2016

    DOI 10.1200/jco.2016.34.15_suppl.e12063 1 Zitation (OpenAlex) Quelle: OpenAlex

  25. SUN-P078: Determination of Malnutrition and Sarcopenia in Geriatric Patients with Gastrointestinal Malignancy

    Clinical Nutrition, 2016

    DOI 10.1016/s0261-5614(16)30421-6 Quelle: OpenAlex

  26. Results of observational study to determine K-ras mutation rates in 2458 patients with metastatic colorectal cancer in Turkey (TURKRAS Study).

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e14516 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  27. Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study

    Molecular and Clinical Oncology, 2015

    DOI 10.3892/mco.2015.633 PMID 26807232 13 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  28. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines

    Cancer Chemotherapy and Pharmacology, 2015

    DOI 10.1007/s00280-015-2756-1 PMID 25925002 12 Zitationen (Europe PMC) Quelle: ORCID

  29. Prognostic effect of tumor location in stage II and III colon cancer

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e14652 Quelle: ORCID

  30. Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells

    Tumor Biology, 2015

    DOI 10.1007/s13277-015-4331-0 PMID 26531719 9 Zitationen (OpenAlex) Quelle: OpenAlex

  31. The Role of Body Mass Index in Triple Negative Breast Cancer

    Oncology Research and Treatment, 2015

    DOI 10.1159/000439551 PMID 26452262 16 Zitationen (OpenAlex) Quelle: OpenAlex

  32. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes?

    Indian Journal of Cancer, 2015

    DOI 10.4103/0019-509x.178382 PMID 26960462 5 Zitationen (OpenAlex) Quelle: OpenAlex

  33. Long-Term Outcomes of Colon Cancer Patients Undergoing Standardized Technique Operation With Curative Intent

    International Surgery, 2015

    DOI 10.9738/intsurg-d-15-00135.1 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  34. SUN-PP124: Correlation between Mini Nutritional Assessment and Hand Grip Strength in Geriatric Patients with Gastrointestinal Cancer

    Clinical Nutrition, 2015

    DOI 10.1016/s0261-5614(15)30275-2 Quelle: OpenAlex

  35. 1917 Prognostic role of surrogate intrinsic subtypes in non-metastatic inflammatory breast cancer

    European Journal of Cancer, 2015

    DOI 10.1016/s0959-8049(16)30866-8 Quelle: OpenAlex

  36. Tumor infiltrating lymphocytes in cutaneous melanoma: Association with tumor characteristics and prognosis.

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e20101 Quelle: OpenAlex

  37. The coexistence of breast cancer and chronic lymphocytic leukemia Case report

    2015

    Quelle: OpenAlex

  38. PharmaNews

    Oncology Research and Treatment, 2015

    DOI 10.1159/000441339 Frei zugänglicher VolltextQuelle: OpenAlex

  39. Reports of Oncological Societies

    Oncology Research and Treatment, 2015

    DOI 10.1159/000441338 Frei zugänglicher VolltextQuelle: OpenAlex

  40. Meetings and Conferences

    Oncology Research and Treatment, 2015

    DOI 10.1159/000441340 Frei zugänglicher VolltextQuelle: OpenAlex

  41. Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.17.7119 PMID 25227800 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  42. Markers to Predict the Efficacy of Bevacizumab in the Treatment of Metastatic Colorectal Cancer

    Tumori Journal, 2014

    DOI 10.1177/1636.17888 PMID 25296585 7 Zitationen (Europe PMC) Quelle: OpenAlex

  43. First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.7.3157 PMID 24815463 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  44. Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report

    Meme sağlığı dergisi/Meme sağlığı dergisi, 2014

    DOI 10.5152/tjbh.2014.1773 2 Zitationen (OpenAlex) Quelle: OpenAlex

  45. Case Management Based Multidisciplinary Care Protocol In The Palliative Care Of Cancer Patients

    Ağrı - The Journal of The Turkish Society of Algology, 2014

    DOI 10.5505/agri.2014.93585 PMID 24943853 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  46. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)

    Medical Oncology, 2014

    DOI 10.1007/s12032-014-0152-z PMID 25108599 34 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  47. Brain Colorectal Saglam 2014

    2014

    Quelle: OpenAlex

  48. Do High-risk Features Support the Use of Adjuvant Chemotherapy in Stage II Colon Cancer? A Turkish Oncology Group Study

    Tumori Journal, 2014

    DOI 10.1177/030089161410000205 PMID 24852857 26 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  49. Kanser hastasının palyatif bakımında vaka yönetimine dayalı multidispliner bakım protein

    Ağrı - The Journal of The Turkish Society of Algology, 2014

    1 Zitation (OpenAlex) Quelle: OpenAlex

  50. Comparison of Molecular Subtypes of Breast Cancer in Women ≤35 Years and > 35 Years: Does Age Matter?

    Annals of Oncology, 2014

    DOI 10.1093/annonc/mdu329.32 Frei zugänglicher VolltextQuelle: OpenAlex